Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
- 1 July 2014
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 147 (1) , 132-142.e4
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CHepatology, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C†,‡,§,¶Hepatology, 2010
- Risk Factors for Infection During Treatment with Peginterferon alfa and Ribavirin for Chronic Hepatitis CHepatology, 2010
- Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infectionAlimentary Pharmacology & Therapeutics, 2010
- Performance of the Abbott Real-Time PCR Assay Usingm2000spandm2000rtfor Hepatitis C Virus RNA QuantificationJournal of Clinical Microbiology, 2009
- Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose PeginterferonNew England Journal of Medicine, 2008
- Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction–based methodHepatology, 2007
- Risk Factors for Hepatocellular Carcinoma in Patients With Alcoholic or Viral C CirrhosisClinical Gastroenterology and Hepatology, 2006
- Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosisJournal of Viral Hepatitis, 2005